3 Horrendous Healthcare Stocks This Week   2-21-14
Upcoming SlideShare
Loading in...5

3 Horrendous Healthcare Stocks This Week 2-21-14



Which healthcare stocks were the worst of the worst this week?

Which healthcare stocks were the worst of the worst this week?



Total Views
Views on SlideShare
Embed Views



8 Embeds 5,953

http://www.fool.com 5819
http://m.fool.com 52
http://www.barchart.com 42
http://www.dailyfinance.com 25
http://cms.fool.com 8
http://mockup.www.fool.com 3
http://translate.googleusercontent.com 3
http://www.slideee.com 1



Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-affymetrix-inc-shares-dropped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx

3 Horrendous Healthcare Stocks This Week   2-21-14 3 Horrendous Healthcare Stocks This Week 2-21-14 Presentation Transcript

  • 3 Horrendous Health-Care Stocks This Week
  • While the victors celebrated in Sochi this week, some Olympians felt the agony of defeat. The same was true in the world of health care. Source: Wikimedia Commons.
  • Onconova Therapeutics (Nasdaq: ONTX) The stock of the biopharmaceutical firm focusing on cancer drugs plunged nearly 38% for the week.
  • Why Onconova nosedived • It announced disappointing results for phase 3 study of rigosertib. • Rigosertib failed to meet its primary endpoint of median overall survival. • The study focused on use of the drug in the treatment of myelodysplastic syndrome, or MDS, in high-risk patients. • Another phase 2 study is under way for rigosertib in treating lower-risk MDS patients.
  • Medbox (NasdaqOTH: MDBX) Shares of this medical marijuana dispensing equipment maker careened more than 24% this week.
  • Why Medbox shares got clobbered • The company was the target of a damaging online article by Citron Research’s Andrew Left. • Left called Medbox’s stock “worthless” and accused the company of fraud. • Medbox publicly acknowledged some accounting errors that were corrected. • Medbox’s largest shareholder and chairman, Vincent Mehdizadeh, responded with a scathing criticism of Andrew Left.
  • GW Pharmaceuticals (Nasdaq: GWPH) The stock of the pharmaceutical firm focusing on medical marijuana fell nearly 9% this week.
  • Why GW shares weren’t buzzing • It was attacked by a short-seller, Infitialis, in a blog post. • The blogger listed multiple issues with GW Pharmaceuticals, including being overhyped as a marijuana play and overvalued. • The stock was hit hard initially, but recovered somewhat.
  • Best shot at bouncing back? • None of this week’s horrendous stocks look very promising. • Onconova still has a phase 2 study under way for rigersitib in treating lower-risk MDS, but it’s probably something of a long shot. • While short-sellers attacking Medbox and GW Pharmaceuticals don’t have the purest of motives, both stocks do appear to be overvalued. • Investors probably should consider looking elsewhere.
  • Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!